Aequus Pharmaceuticals Inc (AQS : TSX-V)
Common Stock
$0.01
CAD
+0.00 (%)
Last updated: 2026-04-10
Get AQS alerts:
AQS
Aequus Pharmaceuticals Inc
WealthAwesomePerformance
1 Day
+0.00%
1 Week
+0.00%
1 Month
+0.00%
YTD
+0.00%
Key Statistics
Market Cap
$663,172
52W High
$0.01
52W Low
$0.01
P/E Ratio
-
50 Day MA
$0.01
200 Day MA
$0.01
Beta
-0.29
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 4/10/2026 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | 0 |
| 4/9/2026 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | 0 |
| 4/8/2026 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | 0 |
| 4/7/2026 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | 0 |
| 4/6/2026 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | 0 |
| 4/2/2026 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | 0 |
| 4/1/2026 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | 0 |
| 3/31/2026 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | 0 |
| 3/30/2026 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | 0 |
| 3/27/2026 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | 0 |
Analyst Price Targets
Based on analyst covering AQS
Wall Street analysts forecast AQS stock price to rise 50300.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.52
+50300.0% Upside
Current Price
C$0.01
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on AQS's historical volatility
30-Day Vol
0.0%
Annualized
90-Day Vol
0.0%
Annualized
Trend (90d)
+0.0%
Annualized drift
90d Mean
C$0.01
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.01 | C$0.01 – C$0.01 |
| 60 trading days | C$0.01 | C$0.01 – C$0.01 |
| 90 trading days | C$0.01 | C$0.01 – C$0.01 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Aequus Pharmaceuticals Inc
Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company offers ZIMED PF, a preservative-free bimatoprost prescription drug for the for the reduction of elevated interocular pressure in patients with open angle glaucoma or ocular hypertension. It also develops REV-0100, which is in pre-clinical trial for the treatment of stargardt disease. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.
Financials
- Revenue (TTM)
- $918,468
- EBITDA
- $-2.37M
- Profit Margin
- -71.46%
- ROE (TTM)
- -1569.60%
- EPS (Diluted)
- -0.02
- Book Value
- -0.05
Classification
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About AQS
Market movers
Recent TSX-V movers
Top 1-day gainers — updated from our Canadian movers feed.